secwatch.observer — SEC 8-K summary
======================================

Issuer:     Disc Medicine, Inc. (IRON)
CIK:        0001816736
Form:       8-K
Filed at:   2025-10-17T23:59:59+00:00
Accession:  0001193125-25-242026
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Disc Medicine receives FDA priority voucher for bitopertin in EPP; review time cut to 1-2 months
--------------------------------------------------------------------------------

- FDA granted CNPV for bitopertin in erythropoietic protoporphyria (EPP) including X-linked protoporphyria.
- NDA submitted September 2025 under accelerated approval pathway for patients aged 12+.
- CNPV program reduces standard FDA review to 1-2 months; includes rolling review and enhanced communications.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1816736/000119312525242026/0001193125-25-242026-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1816736/000119312525242026/iron-20251016.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-242026

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer